Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-04-26 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
董事会议事规则
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of 科兴生物制药股份有限公司 (Sinovac Biotech Co., Ltd.). It details the internal rules, responsibilities, meeting procedures, voting rules, and duties of the board members. There is no financial data, no audit information, no earnings or capital updates, no voting results, no legal proceedings, and no mention of any report publication or announcement. The content is focused on governance structure and board management practices. Therefore, this document fits the category of Governance Information (CGR). The document length is 9409 characters, which is substantive and consistent with a governance report rather than a brief announcement or certification.
2024-04-26 Chinese
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, use, supervision, and responsibilities related to the company's raised funds. It references regulatory requirements from Chinese securities laws and stock exchange rules, and outlines procedures for handling raised capital, including storage, usage, changes in investment direction, and reporting. The document is a formal policy or system document rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content is focused on the management and regulatory compliance of fundraising capital, which aligns with a Capital/Financing Update (CAP) category, as it relates to the company's fundraising and capital management activities.
2024-04-26 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled as the Articles of Association (章程) of 科兴生物制药股份有限公司 (Kexing Biopharm Co., Ltd.) dated April 2024. It contains detailed company governance rules, shareholder rights, board structure, meeting procedures, and other internal regulations. It references relevant laws and stock exchange listing rules. The content is a comprehensive governance document rather than a report of financial results, meeting minutes, or announcements. It is not an Annual Report, Interim Report, or any financial statement. It is not a proxy statement or voting results announcement. It is not a call transcript or earnings release. The document is a detailed governance framework for the company, which fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full governance document, not just an announcement or summary.
2024-04-26 Chinese
关于会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (大华会计师事务所) engaged for the 2023 annual financial report and internal control audit of 科兴生物制药股份有限公司. It details the qualifications, independence, quality control, and audit process of the accounting firm for the 2023 audit. The document does not contain the actual financial statements or audit results but is an assessment of the auditor's performance and compliance with regulations. It is not the audit report itself nor the full annual report. Given the content and purpose, this fits the category of an Audit Report / Information (AR), which includes standalone audit reports and evaluations related to audit activities but excludes full annual reports. The document length is 3077 characters, which is sufficient for a detailed audit evaluation but not a full annual report. Therefore, the classification is AR with high confidence. FY 2023
2024-04-26 Chinese
董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines related to independent directors and their independence evaluation. The content is focused on governance and compliance with listing rules, specifically about board members' independence. It does not contain financial data, earnings, or report publication announcements. It is a governance-related disclosure about board members' status and independence, fitting the Governance Information (CGR) category.
2024-04-26 Chinese
2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls over financial reporting as of December 31, 2023. The content focuses on the audit of internal controls rather than the full annual financial statements or management discussion. The document length is short (1169 characters), and it contains an audit opinion on internal control effectiveness. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the document is classified as AR with high confidence. FY 2023
2024-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.